A daily GLP-1 inhibitor class injection, Victoza remains an important drug ... GLP-1 class thanks to its more patient-friendly weekly dosing schedule. Novo Nordisk has also launched its own ...

Victoza offers a second option in these cases, he added. Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling ...